CervoMed (CRVO) Projected to Post Quarterly Earnings on Friday

CervoMed (NASDAQ:CRVO) is anticipated to announce its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $1.79 million for the quarter.

CervoMed (NASDAQ:CRVO) last issued its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The company had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Stock Performance

Shares of NASDAQ:CRVO opened at $8.50 on Friday. The business’s 50-day simple moving average is $3.85 and its 200 day simple moving average is $7.69. The company has a market cap of $73.98 million, a P/E ratio of -4.19 and a beta of 1.84. CervoMed has a one year low of $1.80 and a one year high of $25.92.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Canaccord Genuity Group lifted their target price on CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, March 18th. Morgan Stanley restated an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Roth Capital upgraded CervoMed to a “strong-buy” rating in a research note on Thursday, December 5th. Chardan Capital raised shares of CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Thursday, March 13th. Finally, HC Wainwright cut shares of CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.50.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.